Regeneron Acquires UK-Based Eye Drug Developer Oxular

Acquisition:
Regeneron has acquired Oxular, a UK-based company specializing in retinal therapeutics development5.

Oxular’s Focus:
Oxular is known for developing novel drug/device combination treatments for sight-threatening retinal disorders, aiming to provide safe, durable therapeutics precisely delivered to specific ocular tissues3.

Previous Financing:
Oxular had previously raised $37 million in financing led by Forbion to fund Phase 2 human clinical studies for its lead asset, OXU-001, a 12-month treatment for diabetic macular edema (DME)1.

Regeneron’s Expansion:
This acquisition aligns with Regeneron’s strategy to expand its portfolio in ocular diseases, following its collaboration with Alnylam on RNAi therapeutics and its acquisition of Decibel Therapeutics for gene therapy programs in hearing loss2 4.

Oxular’s Pipeline:
Oxular’s product pipeline includes treatments for prevalent retinal diseases like DME and age-related macular degeneration (AMD), as well as rare and orphan indications such as ocular cancers1 3.